- Home
- GTX vs NAMS Comparison
GTX vs NAMS Comparison
Compare GTX & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GTX | NAMS |
|---|---|---|
| Founded | 2018 | 2019 |
| Country | Switzerland | Netherlands |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.1B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | GTX | NAMS |
|---|---|---|
| Price | $16.58 | $35.24 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | $16.33 | ★ $45.80 |
| AVG Volume (30 Days) | ★ 2.4M | 1.1M |
| Earning Date | 10-23-2025 | 11-05-2025 |
| Dividend Yield | ★ 1.93% | N/A |
| EPS Growth | ★ 55.30 | N/A |
| EPS | ★ 1.57 | N/A |
| Revenue | ★ $3,537,000,000.00 | $35,243,000.00 |
| Revenue This Year | $3.74 | N/A |
| Revenue Next Year | $2.94 | N/A |
| P/E Ratio | $10.54 | ★ N/A |
| Revenue Growth | N/A | ★ 4.91 |
| 52 Week Low | $7.02 | $14.06 |
| 52 Week High | $17.91 | $42.00 |
Technical Indicators
Market Signals| Indicator | GTX | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 54.85 | 41.95 |
| Support Level | $16.50 | $34.52 |
| Resistance Level | $17.24 | $42.00 |
| Average True Range (ATR) | 0.43 | 2.02 |
| MACD | -0.09 | -0.66 |
| Stochastic Oscillator | 60.88 | 9.69 |
Price Performance
Historical ComparisonAbout GTX Garrett Motion Inc.
Garrett Motion Inc designs, manufactures and sells engineered turbocharger and electric-boosting technologies for light and commercial vehicle original equipment manufacturers (OEMs). The company is a technology leader with expertise in delivering products across gasoline, diesel, natural gas and electrified powertrains. The company also sells its technologies in the aftermarket through its distribution network. The company derives maximum of its revenue from Gas and geographically from Europe.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.